Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II)
- 1 April 1992
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 45 (1), 13-19
- https://doi.org/10.1016/0090-8258(92)90484-z
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast-cancer cell line expressing type II estrogen-binding sitesCancer Chemotherapy and Pharmacology, 1991
- Type‐II estrogen binding sites in a lymphoblastoid cell line and growth‐inhibitory effect of estrogen, anti‐estrogen and bioflavonoidsInternational Journal of Cancer, 1990
- Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cellsBritish Journal of Cancer, 1990
- Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growthAnti-Cancer Drugs, 1990
- Type II oestrogen binding sites in acute lymphoid and myeloid leukaemias: growth inhibitory effect of oestrogen and flavonoidsBritish Journal of Haematology, 1990
- Enhanced anti-proliferative action of busulphan by quercetin on the human leukaemia cell line K562British Journal of Cancer, 1989
- Enhancement of the antiproliferative effect of cis‐diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase CInternational Journal of Cancer, 1988
- Bioflavonoid interaction with rat uterine type ii binding sites and cell growth inhibitionJournal of Steroid Biochemistry, 1988
- Effect of ellagic acid and hydroxylated flavonoids on the tumorigenicity of benzo[a]pyrene and (±)-7β, 8α-dihydroxy-9α, 10α-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene on mouse skin and in the newborn mouseCarcinogenesis: Integrative Cancer Research, 1985
- Flavonoids, a class of natural products of high pharmacological potencyBiochemical Pharmacology, 1983